Why Is PROTAGONIST THERAPEU (PTGX) Stock Up Today?

Protagonist Therapeutics Inc. stock rose 4.65% to $138.16 on Friday, driven by a corporate announcement regarding the granting of inducement awards. The stock opened at $132.41 and reached an intraday high of $138.60 at 10:05 AM ET before settling near the session’s peak. The move comes amid recent analyst upgrades and broader market interest in biotech developments.

What Happened

The company disclosed that it granted stock options and restricted stock units (RSUs) under Nasdaq Rule 5635(c)(4) to induce new employees. The options carry an exercise price of $135.46 and vest over four years, while the RSUs also vest annually over the same period. This move is consistent with industry practices to attract talent in the biotech sector. The announcement was reported by StockTitan and appears to have triggered investor interest in the stock. Recent analyst activity also includes upgrades from Barclays and Truist Securities, both of which raised their price targets for PTGX to $151 and $145 respectively.

What The Data Shows

The stock’s intraday performance was volatile, with a low of $129.52 and a high of $138.60. Volume remained light at 0.0M shares traded, which is 0.1 times the 3-month daily average. Over the past eight sessions, the stock had declined 1.3% from $138.80 to $137.07. Insider transactions in the last 90 days totaled five sales worth $16.4 million, with no insider buying reported. Meanwhile, the stock is currently trading within its 52-week range of $50.48 to $141.10, near its recent high.

What To Watch

The stock is currently unprofitable with a trailing twelve-month EPS of -1.79 and a net margin of -154.9%. Investors should monitor the company’s upcoming developments and any changes in analyst coverage. No earnings date was provided in the data.